

Clinical Trial Protocol

Iranian Registry of Clinical Trials

23 Jun 2026

The effectiveness of memantin in the treatment of adult with attention deficit hyperactivity disorder

Protocol summary

Summary

The purpose is to study the efficacy of Memantin in the treatment of adult attention-deficit hyperactivity disorder (ADHD). Forty subjects between 18-45 years who clearly meet diagnostic criteria for adult ADHD, from parents and siblings of children with ADHD who are referred to child and adolescent psychiatric clinic of Sanandaj Behsat hospital will assign. Inclusion criteria: confirm of symptoms of ADHD in childhood & diagnosis of ADHD on clinical psychiatric interview. Exclusion criteria: any other psychiatric disorder and physical illness. This is a double blind randomized clinical trial study. Participants will be randomly allocated to receive Memantin (10 mg/day and will be titrated up to 20 mg/day after a week) and placebo for 6 weeks. Patients will assess at baseline, 3 and 6 weeks after the medication start with Adult Conner's questionnaires for assessing severity of symptoms of ADHD. Side effects will systematically record throughout the study and will assess using a checklist that comprises side effects by psychiatrist on weeks 1, 3 and 6.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016053028182N1**

Registration date: **2017-01-10, 1395/10/21**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2017-01-10, 1395/10/21

Registrant information

Name

Soleiman Mohammadzadeh

Name of organization / entity

Kurdistan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 87 3323 2168

Email address

dr.mohammadzadeh86@muk.ac.ir

Recruitment status

Recruitment complete

Funding source

Kurdistan University of Medical Sciences

Expected recruitment start date

2016-03-19, 1394/12/29

Expected recruitment end date

2017-03-20, 1395/12/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effectiveness of memantin in the treatment of adult with attention deficit hyperactivity disorder

Public title

Use of memantin in treatment of adult with attention deficit hyperactivity disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 18 to 45 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except Oppositional Defiant disorder; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure

disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute: Pregnant and lactating women

Age

From **18 years** old to **45 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Kurdistan University of Medical Sciences

Street address

Pasdaran Street, Kurdistan University of Medical Sciences

City

Sanandaj

Postal code

Approval date

2015-08-15, 1394/05/24

Ethics committee reference number

MUK.REC.1394.145

Health conditions studied

1

Description of health condition studied

Adult ADHD (Attention-deficit hyperactivity disorder)

ICD-10 code

F90.0

ICD-10 code description

Disturbance of activity and attention

Primary outcomes

1

Description

Improvement in hyperactivity symptom

Timepoint

Baseline, third and sixth weeks after intervention

Method of measurement

Conners' Adult ADHD Rating Scales-Self-Report

2

Description

Improvement in Impulsivity symptoms

Timepoint

Baseline, third and sixth weeks after intervention

Method of measurement

Conners' Adult ADHD Rating Scales-Self-Report

3

Description

Improvement in Attention-deficit symptoms

Timepoint

Baseline, third and sixth weeks after intervention

Method of measurement

Conners' Adult ADHD Rating Scales-Self-Report

Secondary outcomes

1

Description

drug side effects

Timepoint

third and sixth weeks after intervention

Method of measurement

checklist of side effects

2

Description

Efficacy in more than 50% of reduction in ADHD diagnostic rating scale

Timepoint

six weeks after treatment

Method of measurement

Parent interview

Intervention groups

1

Description

Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (one tablet in the night at 10:00 o'clock, and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8:00 o'clock, one tablet at 10:00 o'clock).

Category

Treatment - Drugs

2

Description

Placebo is prescribed a tablet daily for the first week (one tablet in the night at 10:00 o'clock, and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8:00 o'clock, one tablet at 10:00 o'clock).

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Behsat clinic, Behsat Hospital, Kurdistan University of Medical Sciences

Full name of responsible person

Soleiman Mohammadzadeh

Street address

Behsat Hospital, Vakil Street

City

Sanandaj

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kurdistan University of Medical science

Full name of responsible person

Farzin Rezaei

Street address

Pasdaran Street, Kurdistan University of Medical Sciences

City

Sanandaj

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kurdistan University of Medical science

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Kurdistan University of Medical Sciences

Full name of responsible person

Soleiman Mohammadzadeh

Position

Child and Adolescent Psychiatry

Other areas of specialty/work

Street address

Behsat Hospital, Kurdistan University of Medical Sciences

City

Sanandaj

Postal code

Phone

+98 87 3328 5914

Fax

Email

dr.mohammadzadeh86@gmail.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kurdistan University of Medical Sciences

Full name of responsible person

Soleiman Mohammadzadeh

Position

Child and Adolescent Psychiatry

Other areas of specialty/work

Street address

Behsat Hospital, Vakil Street

City

Sanandaj

Postal code

Phone

+98 87 3328 5914

Fax

Email

dr.mohammadzadeh86@gmail.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Kurdistan University Of Medical Science

Full name of responsible person

Soleiman Mohammadzadeh

Position

Child and Adolescent Psychiatrist, Assistant Professor

Other areas of specialty/work

Street address

Behsat Hospital, Vakil Street

City

Sanandaj

Postal code

Phone

+98 87 3328 5914

Fax

Email

dr.mohammadzadeh86@gmail.com

Web page address

empty

Sharing plan

Informed Consent Form

empty

Deidentified Individual Participant Data Set (IPD)

Clinical Study Report

empty

empty

Study Protocol

Analytic Code

empty

empty

Data Dictionary

Statistical Analysis Plan

empty